Leaving buprenorphine treatment: Patients' reasons for cessation of care
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Many opioid-dependent patients leave treatment prematurely. This study is a planned secondary analysis from a randomized trial of counseling for African Americans (N=297) entering buprenorphine treatment at one of two outpatient programs. This study examines: (1) whether patients’ initial treatment duration intentions prospectively predict retention; and (2) patients’ reasons for leaving treatment. Participants were queried about their treatment duration intentions at treatment entry, and their reasons for leaving treatment at 6-month follow-up. At baseline, 28.0% reported wanting to stay in buprenorphine treatment less than 6 months, while 42.1% actually left buprenorphine treatment within 6 months. However, participants intending short-term buprenorphine at the outset were not at elevated risk of early treatment discontinuation (OR=1.15; p=.65). Participants attributed treatment cessation predominantly to conflicts with staff, involuntary discharge, and perceived inflexibility of the program. Future research should examine patient-centered models of buprenorphine treatment that could improve retention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Degenhardt, L., Bucello, C., Mathers, B., Briegleb, C., Ali, H., Hickman, M., & McLaren, J. (2011) · Addiction · doi:10.1111/j.1360-0443.2010.03140.x · Cited by 856 · cited 4×
“…of opioid use (Stimmel & Rabin, 1974; Stimmel et al., 1977; Kornør, Waal, & Sandvik, 2007), but elevated risk of death as well (Caplehorn, Dalton, Cluff & Petrenas, 1994; Clausen, Waal, Thoresen, & Gossop, 2009; Degenhardt et al., 2011; Gibson et al., 2008; Woody, Kane, Lewis, & Thompson, 2007).”
BackgroundInfluentialAmato, L., Davoli, M., A.Perucci, C., Ferri, M., Faggiano, F., & P. Mattick, R. (2005) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2005.02.007 · Cited by 567 · cited 4×
“Opioid agonist medications like methadone and buprenorphine are effective treatments for opioid dependence (Amato et al., 2005; Mattick, Kimber, Breen, & Davoli, 2008).”
BackgroundInfluentialBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
Cited by
Retention in medication-assisted treatment for opiate dependence: A systematic review
Timko, C., Schultz, N. R., Cucciare, M. A., Vittorio, L., & Garrison-Diehn, C. (2016) · Journal of Addictive Diseases · doi:10.1080/10550887.2016.1100960 · Cited by 489
Retention of patients in opioid substitution treatment: A systematic review
O’Connor, A. M., Cousins, G., Durand, L., Barry, J., & Boland, F. (2020) · PLOS ONE · doi:10.1371/journal.pone.0232086 · Cited by 298
Discontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes
Bentzley, B. S., Barth, K. S., Back, S. E., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.12.011 · Cited by 176
“More recently, Gryczynski et al. (2013) reported buprenorphine perspectives of participants from a parent randomized clinical trial (Mitchell et al., 2013) comparing levels of counseling intensity in conjunction with BMT at 2 outpatient substance abuse treatment clinics in Baltimore, Maryland.”
InfluentialThe Next Stage of Buprenorphine Care for Opioid Use Disorder
Martin, S. A., Chiodo, L. M., Bosse, J. D., & Wilson, A. (2018) · Annals of Internal Medicine · doi:10.7326/m18-1652 · Cited by 130
Lin, L. A., Bohnert, A. S. B., Blow, F. C., Gordon, A. J., Ignacio, R. V., Kim, H. M., & Ilgen, M. A. (2021) · Addiction · doi:10.1111/add.15116 · Cited by 108
Metadata
- Authors
- Gryczynski, J., Mitchell, S. G., Jaffe, J. H., O’Grady, K. E., Olsen, Y. K., & Schwartz, R. P.
- Venue
- Journal of Substance Abuse Treatment
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 46
- Issue
- 3
- Pages
- 356-361
- ISSN
- 0740-5472 (ISSN-L)
- OpenAlex
- W1970939183
- Cited by
- 118
- References
- 3
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.